Assembly Biosciences (NASDAQ:ASMB) had its price objective increased by Jefferies Group to $75.00 in a report released on Thursday morning, The Fly reports. Jefferies Group currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently commented on the stock. Zacks Investment Research raised shares of Assembly Biosciences from a hold rating to a buy rating and set a $37.00 price target for the company in a research note on Wednesday, November 15th. BidaskClub cut shares of Assembly Biosciences from a strong-buy rating to a buy rating in a research note on Wednesday, December 6th. ValuEngine cut shares of Assembly Biosciences from a hold rating to a sell rating in a research note on Thursday, December 7th. Finally, B. Riley initiated coverage on shares of Assembly Biosciences in a research note on Friday, January 5th. They set a neutral rating and a $35.00 price target for the company. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $45.50.

How to Become a New Pot Stock Millionaire

Assembly Biosciences (NASDAQ ASMB) opened at $58.14 on Thursday. Assembly Biosciences has a 52 week low of $18.60 and a 52 week high of $59.94. The company has a market cap of $1,177.39, a PE ratio of -19.58 and a beta of 0.57.

In other Assembly Biosciences news, Director William R. Ringo sold 1,000 shares of the business’s stock in a transaction dated Thursday, March 1st. The shares were sold at an average price of $56.37, for a total value of $56,370.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders have sold 3,000 shares of company stock valued at $148,270. 19.60% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in the business. MetLife Investment Advisors LLC purchased a new stake in Assembly Biosciences in the 4th quarter valued at about $326,000. Endurant Capital Management LP purchased a new stake in Assembly Biosciences in the 4th quarter valued at about $430,000. Millennium Management LLC boosted its position in Assembly Biosciences by 30.4% in the 4th quarter. Millennium Management LLC now owns 133,666 shares of the biopharmaceutical company’s stock valued at $6,048,000 after buying an additional 31,195 shares during the period. TIAA CREF Investment Management LLC boosted its position in Assembly Biosciences by 46.8% in the 4th quarter. TIAA CREF Investment Management LLC now owns 72,331 shares of the biopharmaceutical company’s stock valued at $3,273,000 after buying an additional 23,064 shares during the period. Finally, Teachers Advisors LLC boosted its position in Assembly Biosciences by 16.1% in the 4th quarter. Teachers Advisors LLC now owns 28,964 shares of the biopharmaceutical company’s stock valued at $1,311,000 after buying an additional 4,025 shares during the period. 77.26% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This report was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.thecerbatgem.com/2018/03/12/assembly-biosciences-asmb-pt-raised-to-75-00.html.

About Assembly Biosciences

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

The Fly

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.